ROLE OF LEPTIN IN OBESITY AND TYPE 2 DIABETES: MECHANISMS, CLINICAL EVIDENCE, AND THERAPEUTIC POTENTIAL
DOI:
https://doi.org/10.22159/ijpps.2026v18i4.57256Keywords:
Obesity, Type 2 diabetes mellitus, Leptin resistance, Insulin sensitivity, Energy homeostasis, Leptin therapyAbstract
Adipocytes are responsible for synthesizing predominantly leptin, a hormone that regulates appetite, energy expenditure, and glucose metabolism. The discovery of leptin in 1994 revolutionized the understanding of systemic energy homeostasis is providing an understanding of obesity and type 2 diabetes mellitus (T2DM) as two connected global health issues. In physiological environments, leptin functions as a satiety signal and metabolic regulator. In obesity and T2DM, however, hyperleptinemia occurs (i.e., elevated levels of leptin) with leptin resistance (i.e., diminished leptin signaling) in which central leptin signaling is impaired regardless of elevated leptin levels. Leptin resistance or malfunction occurring in persons may lose its effects of appetite suppression and metabolic regulation to increase weight gain, insulin-resistance, and disruption of glucose homeostasis.
The review deals with the molecular structure of leptin, functions, and its mechanism in the pathogenesis of obesity and type II diabetes mellitus (T2DM). It further covers the key pathways such as hypothalamic regulation, hepatic glucose production, muscle metabolism, and function in pancreatic β cells. Moreover, clinical observations are reviewed to highlight the therapeutic potential of leptin-targeted therapies, including leptin sensitizers and combination therapeutics. Although effective in treating rare leptin-deficient disorders, leptin replacement therapy has limited usefulness in treatment of common obesity and type II diabetes mellitus because of widespread resistance. To unlock the potential of leptin therapy future research needs to be steered toward restoring leptin-sensitivity, leveraging interactions with the microbiome, and the application of precision medicine approaches.
Downloads
References
1. Obradovic, M., Sudar-Milovanovic, E., Soskic, S., Essack, M., Arya, S., Stewart, A. J., Gojobori, T., &Isenovic, E. R. (2021). Leptin and Obesity: Role and Clinical Implication. Frontiers in endocrinology, 12, 585887. https://doi.org/10.3389/fendo.2021.585887
2. Boutari, C., &Mantzoros, C. S. (2022). A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism: clinical and experimental, 133, 155217. https://doi.org/10.1016/j.metabol.2022.155217
3. Dornbush S, Aeddula NR. Physiology, Leptin. [Updated 2023 Apr 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537038/
4. Kelesidis, T., Kelesidis, I., Chou, S., &Mantzoros, C. S. (2010). Narrative review: the role of leptin in human physiology: emerging clinical applications. Annals of internal medicine, 152(2), 93–100. https://doi.org/10.7326/0003-4819-152-2-201001190-00008.
5. Frühbeck G. (2006). Intracellular signalling pathways activated by leptin. The Biochemical journal, 393(Pt 1), 7–20. https://doi.org/10.1042/BJ20051578
6. Myers MG Jr, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537–556. doi:10.1146/annurev.physiol.70.113006.100707.
7. Suryapani a, uniyal sm. Correlation of leptin and adiponectin levels with metabolic and hormonal profiles in pcos patients: A comparative study with normal controls. Int j curr pharm sci [internet]. 2024 nov. 15 [cited 2025 dec. 22];16(6):62-5. Available from: https://journals.innovareacademics.in/index.php/ijcpr/article/view/52998
8. Yeung AY, Tadi P. Physiology, Obesity Neurohormonal Appetite And Satiety Control. [Updated 2023 Jan 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555906/
9. Myers, M. G., Cowley, M. A., & Münzberg, H. (2008). Mechanisms of leptin action and leptin resistance. Annual review of physiology, 70, 537–556. https://doi.org/10.1146/annurev.physiol.70.113006.100707
10. Manglani, K., Anika, N. N., Patel, D., Jhaveri, S., Avanthika, C., Sudan, S., Alimohamed, Z., & Tiwari, K. (2024). Correlation of Leptin in Patients With Type 2 Diabetes Mellitus. Cureus, 16(4), e57667. https://doi.org/10.7759/cureus.57667
11. Konstantinos Stefanakis, Jagriti Upadhyay, Arantxa Ramirez-Cisneros, Nihar Patel, Akshat Sahai, Christos S. Mantzoros,Leptin physiology and pathophysiology in energy homeostasis, immune function, neuroendocrine regulation and bone health,Metabolism,Volume 161,2024,156056,ISSN 0026-0495,https://doi.org/10.1016/j.metabol.2024.156056.
12. Obradovic M, Sudar-Milovanovic E,Soskic S, Essack M, Arya S,Stewart AJ, Gojobori Tand Isenovic ER (2021) Leptin and Obesity:Role and Clinical Implication. Front. Endocrinol. 12:585887. doi: 10.3389/fendo.2021.585887
13. Sheth N D, Shaker I A, Bidwe S, Diagnostic potential of elevated leptin in metabolic syndrome: A comprehensive review and meta-analysis. Int J Clin Biochem Res 2024;11(4):214-222 https://doi.org/10.18231/j.ijcbr.2024.032
14. Gawali, R., Bahulikar, A., Phalgune, D. S., &Tambolkar, A. (2019). Association between Serum Leptin Levels and Obesity in Type 2 Diabetes Mellitus Patients: A Cross-sectional Study. Journal of Clinical and Diagnostic Research, 13(10), OC17–OC20.DOI: 10.7860/JCDR/2019/42410.13235
15. Perakakis, N., &Mantzoros, C. S. (2024). Evidence from clinical studies of leptin: Current and future clinical applications in humans. Metabolism, 161, 156053. https://doi.org/10.1016/j.metabol.2024.156053
16. Vilariño-García, T.; Polonio-González, M.L.; Pérez-Pérez, A.; Ribalta, J.; Arrieta, F.; Aguilar, M.; Obaya, J.C.; Gimeno-Orna, J.A.; Iglesias, P.; Navarro, J.; et al. Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes. Int. J. Mol. Sci. 2024, 25, 2338.https://doi.org/10.3390/ijms25042338
17. Gómez WA, Humeres G, Orozco-Castaño CA, Cannataro R, Muñoz-Contreras AM, Gómez-Miranda LM, et al. Leptin Signaling and Its Relationship with Obesity-induced Insulin Resistance: A Bioinformatics-assisted Review. Gene Expr. 2025;24(1):56-63. doi: 10.14218/GE.2024.00039
18. Greco, M., De Santo, M., Comandè, A., Belsito, E. L., Andò, S., Liguori, A., & Leggio, A. (2021). Leptin-Activity Modulators and Their Potential Pharmaceutical Applications. Biomolecules, 11(7), 1045. https://doi.org/10.3390/biom11071045
19. Kyriakou E, Schmidt S, Mantzoros CS. Targeting leptin resistance in obesity and metabolic disease. Metabolism. 2018;85:1–15. doi:10.1016/j.metabol.2018.03.004
20. Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, et al. Antiobesity effects of the β-cell hormone amylin in combination with leptin in diet-induced obese rodents and humans. Proc Natl Acad Sci U S A. 2008;105(20):7257–7262. doi:10.1073/pnas.0706473105
21. Altarejos JY, Montrose-Rafizadeh C, Smith EP, et al. Pharmacologic activation of the leptin receptor with a monoclonal antibody agonist and implications for combination therapy with incretin-based agents. Sci Transl Med. 2023;15(703):eabq1234. doi:10.1126/scitranslmed.abq1234
22. Ravussin, E., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009). Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring, Md.), 17(9), 1736–1743. https://doi.org/10.1038/oby.2009.184
23. de Assis, G. G., & Murawska-Ciałowicz, E. (2023). Exercise and Weight Management: The Role of Leptin-A Systematic Review and Update of Clinical Data from 2000-2022. Journal of clinical medicine, 12(13), 4490. https://doi.org/10.3390/jcm12134490
24. Aragonès, G., Ardid-Ruiz, A., Ibars, M., Suárez, M., &Bladé, C. (2016). Modulation of leptin resistance by food compounds. Molecular nutrition & food research, 60(8), 1789–1803. https://doi.org/10.1002/mnfr.201500964
25. Tam, C. S., Lecoultre, V., &Ravussin, E. (2011). Novel strategy for the use of leptin for obesity therapy. Expert opinion on biological therapy, 11(12), 1677–1685. https://doi.org/10.1517/14712598.2011.619974
26. van Son, J., Koekkoek, L. L., La Fleur, S. E., Serlie, M. J., &Nieuwdorp, M. (2021). The Role of the Gut Microbiota in the Gut-Brain Axis in Obesity: Mechanisms and Future Implications. International journal of molecular sciences, 22(6), 2993. https://doi.org/10.3390/ijms22062993
27. Nikolaos Perakakis, Christos S. Mantzoros,Evidence from clinical studies of leptin: current and future clinical applications in humans, Metabolism, Volume 161, 2024, 156053, ISSN 0026-0495, https://doi.org/10.1016/j.metabol.2024.156053.
28. Rajyalakshmi DeviP, VinyasM, Vinod KumarN, SrinathM, Mote. Comparative anti-obesity activity of probiotics with short-chain fatty acids (SCFAs) through GLP 1 andPYY activityin high-fat diet-inducedobesity in rats. TexilaInt J Public Health. 2024;12(3):Art.007. doi: 10.21522/TIJPH.2013.12.03.2.
29. DeviPR, SrinathM, VenuT, NelsonVK, VinyasM. Acute and sub-acute toxicological study of short-chain fattyacids (SCFAs) in rats. IJASE. 2025;11(4):4424-34. doi: 10.29294/IJASE.11.4.2025.4424-4434.
30. Mohammad M, Olabi A, Lahdo R. Investigating the relationship between serum leptin levels and C-reactive protein in polycystic ovary syndrome (PCOS) patients. Innovare J Med Sci. 2016;4(3):10-13. Available from: https://journals.innovareacademics.in/index.php/ijms/article/view/12508
31. Devi, p. R., Srinath, m., Reddy, b. M., Chaitanya, k. R. V. S., & Vinyas, m. (2025). Investigating The Role Of Probiotics And Short-Chain Fatty Acids (Scfas) In Modulating Leptin For Improved Anti-Diabetic Effects In Streptozotocin-Nicotinamide Induced Type Ii Diabetes In Rats. International Journal Of Applied Pharmaceutics, 17(6), 560–567. Https://Doi.Org/10.22159/Ijap.2025v17i6.54383
Published
How to Cite
Issue
Section
Copyright (c) 2026 Rajyalakshmi devi Pothula, Dr. Mote Srinath
This work is licensed under a Creative Commons Attribution 4.0 International License.